Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.
CStone Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of sugemalimab as a monotherapy for unresectable stage III non-small cell lung cancer (NSCLC) in Europe. This development, based on the pivotal Phase III GEMSTONE-301 study, could solidify sugemalimab’s role as a core immunotherapy for lung cancer, enhancing its market presence and commercial potential. If approved, it will become the second PD-(L)1 antibody available in Europe for stage III NSCLC, addressing a critical unmet need and bringing new hope to patients.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. Its pipeline includes promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
Average Trading Volume: 22,790,046
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.91B
Learn more about 2616 stock on TipRanks’ Stock Analysis page.